Related Experiment Video

Updated: Apr 5, 2026

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

40.2K

Profile of veliparib and its potential in the treatment of solid tumors

Lars M Wagner1

  • 1Division of Pediatric Hematology/Oncology, University of Kentucky, Lexington, KY, USA.

Oncotargets and Therapy
|August 8, 2015
PubMed

Insights

Veliparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor, shows promise in treating cancers with DNA repair defects. Clinical trials are evaluating its efficacy, toxicity, and optimal use in combination therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Poly(ADP-ribose) polymerase (PARP) is crucial for DNA damage repair.
  • PARP inhibitors are effective in tumors with DNA repair deficiencies or when combined with DNA-damaging agents.

Purpose of the Study:

  • To review the pharmacology, mechanism of action, toxicity, and clinical trial activity of the PARP inhibitor veliparib.
  • To discuss resistance mechanisms, biomarkers, patient selection, and combination therapies for veliparib.

Main Methods:

  • Review of clinical trial data for veliparib.
  • Pharmacological and mechanistic analysis of veliparib.
  • Discussion of resistance, biomarkers, and therapeutic strategies.

Main Results:

  • Veliparib is an oral PARP inhibitor currently in clinical trials.
  • Its efficacy is being assessed in various cancer types, particularly those with DNA repair defects.
  • Toxicity and potential combination therapies are under investigation.

Conclusions:

  • Veliparib represents a promising therapeutic agent for specific cancer patient populations.
  • Further research is needed to optimize its use through patient selection and combination strategies.
Keywords:
BRCAPARP inhibitorsolid tumorsveliparib

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
743
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
612